you can try to mix words as much as you like.
Bone marrow derived MSC are known for their issues and once again, MSB has twice been knocked back on their proofs that each bag of RemL does the same thing as the last bag of RemL.
Why is it ethical that a the FDA should approve a therapy for children that has failed to prove that one child will receive the therapeutic benefit and the other doesn't?
what world do you live in - so obsessed that the FDA should bend the rules for acute children illness?
Cell Therapy News/Articles, page-17037
-
- There are more pages in this discussion • 784 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |